InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

C4 Therapeutics, Inc.

CCCC Clue Score37
United States Fiscal year ends December CIK 0001662579
$3.16 +10.88% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $3.16 −92.44% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 2 Oct 2020. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2019Operating income−35.5Net income−34.1Fiscal year 2020Operating income−60.4Net income−66.3Fiscal year 2021Revenue45.8Operating income−82.1Net income−83.9EPS, diluted−1.82Fiscal year 2022Revenue31.1 −32.1%Operating income−129.5Net income−128.2EPS, diluted−2.62Fiscal year 2023Revenue20.8 −33.3%Operating income−139.0Net income−132.5EPS, diluted−2.67Fiscal year 2024Revenue35.6 +71.4%Operating income−119.6Net income−105.3EPS, diluted−1.52Fiscal year 2025Revenue35.9 +1.0%Operating income−115.2Net income−105.0EPS, diluted−1.27
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue n/a n/a 45.8 31.1 20.8 35.6 35.9
Growth −32.1% −33.3% +71.4% +1.0%
Operating income −35.5 −60.4 −82.1 −129.5 −139.0 −119.6 −115.2
Net income −34.1 −66.3 −83.9 −128.2 −132.5 −105.3 −105.0
Growth
EPS, diluted n/a n/a −1.82 −2.62 −2.67 −1.52 −1.27
Growth

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2019Fiscal year 2020Fiscal year 2021Operating margin−179.4%Net margin−183.2%Free cash flow margin−192.7%Fiscal year 2022Operating margin−416.6%Net margin−412.2%Free cash flow margin−358.4%Fiscal year 2023Operating margin−669.8%Net margin−638.3%Free cash flow margin−523.0%Fiscal year 2024Operating margin−336.1%Net margin−296.0%Free cash flow margin−183.6%Fiscal year 2025Operating margin−320.5%Net margin−292.1%Free cash flow margin−276.2%
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin n/a n/a −179.4% −416.6% −669.8% −336.1% −320.5%
Net margin n/a n/a −183.2% −412.2% −638.3% −296.0% −292.1%
Free cash flow margin n/a n/a −192.7% −358.4% −523.0% −183.6% −276.2%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2019Operating cash flow55.6Capital expenditure−1.3Free cash flow54.3Buybacks−0.0Fiscal year 2020Operating cash flow−67.2Capital expenditure−0.7Free cash flow−67.9 −225.1%Buybacks−0.2Fiscal year 2021Operating cash flow−87.0Capital expenditure−1.3Free cash flow−88.2Fiscal year 2022Operating cash flow−105.9Capital expenditure−5.5Free cash flow−111.4Buybacks0.0Fiscal year 2023Operating cash flow−106.8Capital expenditure−1.7Free cash flow−108.5Buybacks−0.1Fiscal year 2024Operating cash flow−65.2Capital expenditure−0.2Free cash flow−65.3Buybacks−0.2Fiscal year 2025Operating cash flow−98.7Capital expenditure−0.6Free cash flow−99.3Buybacks−0.2
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow 55.6 −67.2 −87.0 −105.9 −106.8 −65.2 −98.7
Capital expenditure −1.3 −0.7 −1.3 −5.5 −1.7 −0.2 −0.6
Free cash flow 54.3 −67.9 −88.2 −111.4 −108.5 −65.3 −99.3
Growth −225.1%
Buybacks −0.0 −0.2 n/a 0.0 −0.1 −0.2 −0.2

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2019Cash90.5Shareholders’ equity−112.0Fiscal year 2020Cash181.7Total debt10.1Net cash (debt)171.7Shareholders’ equity280.8Debt to equity0.04Fiscal year 2021Cash76.1Total debt10.8Net cash (debt)65.4Shareholders’ equity389.6Debt to equity0.03Fiscal year 2022Cash29.8Total debt11.5Net cash (debt)18.3Shareholders’ equity289.2Debt to equity0.04Fiscal year 2023Cash126.6Total debt0.0Net cash (debt)126.6Shareholders’ equity246.1Debt to equity0.00Fiscal year 2024Cash55.5Shareholders’ equity216.0Fiscal year 2025Cash74.6Shareholders’ equity256.6
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 90.5 181.7 76.1 29.8 126.6 55.5 74.6
Total debt n/a 10.1 10.8 11.5 0.0 n/a n/a
Net cash (debt) n/a 171.7 65.4 18.3 126.6 n/a n/a
Shareholders’ equity −112.0 280.8 389.6 289.2 246.1 216.0 256.6
Debt to equity n/a 0.04 0.03 0.04 0.00 n/a n/a

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Cash flow

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Operations
55.6 −67.2 −87.0 −105.9 −106.8 −65.2 −98.7
Growth −220.9%
Investment
−1.3 −0.7 −1.3 −5.5 −1.7 −0.2 −0.6
calc 54.3 −67.9 −88.2 −111.4 −108.5 −65.3 −99.3
Growth −225.1%
calc n/a n/a −1.92 −2.28 −2.19 −0.94 −1.20
−1.6 −190.5 −189.3 58.4 158.3 −51.3 −8.6
Financing
0.2 348.9 171.4 1.1 45.5 45.3 126.4
−0.0 −0.2 n/a 0.0 −0.1 −0.2 −0.2

Lines marked calc are worked out here from filed figures; point at one for how. Capital expenditure, dividends and buybacks are shown as money out, so negative.